



US00D914095S

(12) **United States Design Patent** (10) **Patent No.:** **US D914,095 S**
Maguire et al. (45) **Date of Patent:** **** Mar. 23, 2021**

(54) **LABEL**

(71) Applicant: **Glenmark Pharmaceuticals Ltd.,**
Mumbai (IN)
(72) Inventors: **Grace M. Maguire,** Paramus, NJ (US);
An Phan, Paramus, NJ (US);
Madhurima Gupta Jain, Mumbai
(IN); **Carole Capella,** Mahwah, NJ
(US)

(73) Assignee: **Glenmark Pharmaceuticals Ltd.,**
Mumbai (IN)

(**) Term: **15 Years**

(21) Appl. No.: **29/647,873**

(22) Filed: **May 16, 2018**

(51) **LOC (13) Cl.** **19-08**

(52) **U.S. Cl.**
USPC **D20/27**

(58) **Field of Classification Search**
USPC 40/368, 446, 452, 453, 488, 538, 541,
40/542, 545-548, 563, 564, 568,
40/570-574, 582, 584, 594, 596, 600,
40/605, 615, 617, 618, 624; 362/217,
362/551, 559, 562, 565, 806, 811, 812;
D9/430, 432, 434; D10/109.1, 109.2,
D10/113.4; D19/1, 6, 9, 10; D20/10, 11,
D20/19, 22-28, 40, 99; D24/100-234;
D26/31

CPC G06F 3/0481; G06F 17/50; G09F 1/00;
G09F 1/02; G09F 2007/122; G09F
2007/1807; G09F 2003/023; G09F
2003/0261; G09F 2003/0264; G09F
2013/0427; G09F 2013/0495; G09F
2013/1895; G09F 3/206; G09F 7/00;
G09F 13/00; G09F 13/04; G09F 13/06;
G09F 13/18; G09F 13/22; G09F 13/24;
G09F 13/26; G09F 7/16; G09F 15/00;
G09D 3/00; H04N 1/00424

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

D405,118 S * 2/1999 Murphy, Sr. D20/11
D428,053 S 7/2000 Leon
D428,439 S 7/2000 Leon
D430,902 S * 9/2000 Aakermann D20/22

(Continued)

FOREIGN PATENT DOCUMENTS

CN 3043038 4/1996
CN 3299186 6/2003

(Continued)

OTHER PUBLICATIONS

“Olanzapine—olanzapine tablet, orally disintegrating.” *dailymed.nlm.nih.gov*. Revised Dec. 2016. Accessed Apr. 27, 2020. Available online at URL: <https://dailymed.nlm.nih.gov/daily/archives/fdaDrugInfo.cfm?archiveid=240225> (Year: 2016).*

(Continued)

Primary Examiner — Christian P. McLean
(74) *Attorney, Agent, or Firm* — Blank Rome LLP


(57) **CLAIM**

The ornamental design for a label, as shown and described.

DESCRIPTION

FIG. 1 illustrates a front view of a first embodiment of a label showing the new design; and, FIG. 2 illustrates a front view of a second embodiment of a label showing the new design. The shading depicts a contrast in appearance. The broken lines illustrate portions of the label that form no part of the claimed design.

1 Claim, 1 Drawing Sheet



(56)

References Cited

U.S. PATENT DOCUMENTS

D436,183 S * 1/2001 Stevens D20/22
 D456,837 S 5/2002 Leon
 D469,129 S * 1/2003 Fabel D20/22
 D478,008 S 8/2003 Rade et al.
 D483,405 S * 12/2003 Bratter D19/1
 D524,652 S 7/2006 Harada et al.
 D536,038 S 1/2007 Frendberg et al.
 D569,423 S 5/2008 Lasch et al.
 D572,305 S 7/2008 Lasch et al.
 D578,569 S 10/2008 Lasch et al.
 D579,044 S 10/2008 Lasch et al.
 7,448,153 B2 * 11/2008 Maliner G09F 3/10
 40/310
 D586,210 S * 2/2009 Noschang D9/434
 D587,111 S * 2/2009 Seol D5/56
 D593,600 S 6/2009 Lasch et al.
 D603,701 S * 11/2009 Seol D9/432
 D608,636 S * 1/2010 Seol D9/432
 D629,688 S * 12/2010 Bolsinger D9/434
 D632,573 S * 2/2011 Bolsinger D9/434
 D632,741 S 2/2011 Meyer
 D633,150 S 2/2011 Tesnar et al.
 D634,190 S 3/2011 Lowery et al.
 D635,017 S * 3/2011 Kerr D5/25
 D645,093 S * 9/2011 Manko D20/27
 D647,795 S * 11/2011 Eaton D9/434
 D651,512 S * 1/2012 Eaton D9/435
 D660,145 S * 5/2012 Tekulve D9/432
 D666,907 S 9/2012 Dowden et al.
 D669,790 S * 10/2012 Powers D9/434
 D675,521 S 2/2013 Gregory et al.
 D676,490 S * 2/2013 Bratter D19/1
 D678,764 S * 3/2013 Powers D9/434
 D679,333 S * 4/2013 Jabara D20/27
 D682,356 S * 5/2013 Zhong D20/23
 D683,045 S * 5/2013 Domack D24/225
 D683,215 S * 5/2013 Thompson D9/432
 D683,216 S * 5/2013 Thompson D9/432
 D683,217 S * 5/2013 Thompson D9/432
 D683,218 S * 5/2013 Thompson D9/434
 D683,398 S * 5/2013 Bratter D19/1
 D684,631 S * 6/2013 Cohen D20/11
 D693,681 S * 11/2013 Allen D9/434
 D703,041 S * 4/2014 Abel B65D 85/00
 D9/434
 D703,533 S * 4/2014 Merchant D9/434
 D709,954 S * 7/2014 Kasper D20/27
 D714,141 S 9/2014 Robinson
 D721,403 S * 1/2015 Moore D20/27
 D727,429 S * 4/2015 Boyer D20/27
 D728,017 S 4/2015 Liddy et al.
 D734,388 S 7/2015 Lin et al.
 D767,397 S * 9/2016 Leuliet D9/457
 D768,237 S 10/2016 Huang
 D774,400 S * 12/2016 Miyazaki D9/434
 D778,167 S * 2/2017 Mochizuki D9/432
 D786,680 S * 5/2017 Merchant D9/516
 D788,846 S 6/2017 Craig, II
 D796,955 S * 9/2017 Leuliet D9/457
 D800,573 S * 10/2017 Mochizuki D9/624
 D801,432 S 10/2017 Aoki et al.
 D834,093 S * 11/2018 Fahsbender D20/27
 D835,193 S * 12/2018 Aoyagi D20/27
 D835,988 S * 12/2018 Pryor D9/432
 D841,016 S * 2/2019 Kimura D14/485
 D847,856 S * 5/2019 Kim D14/488
 D863,057 S * 10/2019 Riffe D9/434
 D863,955 S * 10/2019 Riffe D9/434

D863,956 S * 10/2019 Riffe D9/434
 D863,957 S * 10/2019 Riffe D9/434
 D867,130 S * 11/2019 Merchant D9/434
 D871,211 S * 12/2019 Marcano D9/434
 D876,218 S * 2/2020 Thompson D9/432
 D885,180 S * 5/2020 Murchison D9/434
 2003/0075918 A1 * 4/2003 Levine G09F 3/0288
 283/81
 2006/0068145 A1 * 3/2006 Chandaria B42D 5/003
 428/40.1
 2008/0020163 A1 * 1/2008 Salva Calcagno G09F 3/0292
 428/40.1
 2012/0212946 A1 * 8/2012 Shmuel G09F 9/33
 362/184
 2020/0172281 A1 * 6/2020 Matsuoka B65C 3/08

FOREIGN PATENT DOCUMENTS

CN	3319196	9/2003
CN	3379564	7/2004
CN	3393460	9/2004
CN	3447953	5/2005
CN	3464283	7/2005
CN	300776148	5/2008
CN	300801276	7/2008
CN	300822186	8/2008
CN	300932997	5/2009
CN	300992355	8/2009
CN	301049305	10/2009
CN	301072760	12/2009
CN	301078547	12/2009
CN	301091067	12/2009
CN	301237086	5/2010
CN	301352796	9/2010
CN	301553735	5/2011
CN	301590242	8/2011
CN	302082007	9/2012
CN	302631584	11/2013
CN	302721449	1/2014
CN	303020457	12/2014
CN	303378250	9/2015
CN	303606104	4/2016
CN	303653519	4/2016
CN	303877873	10/2016
CN	304139801	5/2017
CN	304169262	5/2017
CN	304180526	6/2017
CN	304349713	11/2017
CN	304394540	12/2017
CN	304394541	12/2017
CN	304427297	12/2017
CN	304450629	1/2018
IN	2686100001	8/2015
MX	0177680001	6/2005
RO	0177680001	1/2007
RO	F011420070001	7/2007

OTHER PUBLICATIONS

“Olanzapine and Fluoxetine—olanzapine and fluoxetine capsule.”
 dailymed.nlm.nih.gov. Revised Jan. 2018. Accessed Apr. 27, 2020.
 Available online at URL: <https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=307609> (Year: 2018).*

“Azithromycin—azithromycin for suspension.” dailymed.nlm.nih.gov.
 Revised Dec. 2019. Accessed Apr. 27, 2020. Available online
 at URL: <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0ab1486a-b890-45a1-9bfc-cf72d7cb9dd1&type=display> (Year: 2019).*

* cited by examiner

FIG. 1




FIG. 2

